Tetra Pharm Technologies is a Danish biopharmaceutical company with a mission to improve quality of life for our patients through affordable, high-quality products.

Our vision is to become a leader in research and development of pharmaceutical drugs for the treatment of diseases related to the endocannabinoid system (ECS), such as neuropathic pain, MS spasms, and mental health disorders.

The endocannabinoid system is a widespread neuromodulatory system that regulates and controls several of the most critical bodily functions, such as learning and memory, emotional processing, sleep, temperature, pain control, inflammatory and immune responses, and appetite.

Research and development are key to Tetra Pharm Technologies’ future success. It is therefore our primary area of focus when it comes to future investments and priorities. We currently have several new formulations indicated for chronic pain and mental health disorders in our clinical pipeline, and we aim to initiate clinical trials on a number of these in the near future to ensure a steady flow of new product launches.

A significant part of the investment into our solid clinical pipeline arises from revenue generated from sales of our portfolio of unlicensed and magistral products providing for a financially sound self-funding business model.

Tetra Pharm Technologies was founded in 2018 by Martin Rose and Jesper Breum who both held leading positions in a number of global pharmaceutical companies.

Based on their experience from the pharmaceutical industry, Martin and Jesper decided to explore their interest in and curiosity for the endocannabinoid system and its inherent potential for improving quality of life for patients suffering from neuropathic pain, MS spasms, and mental health disorders.

The company headquarter is located in Ølstykke, approx. 40 kilometers north of Copenhagen firmly within Medicon Valley – the leading international life science cluster spanning the Greater Copenhagen region and southern Sweden. The state-of-the-art site spans 4,000 sqm of R&D facilities, production, and corporate administration. In addition, Tetra Pharm Technologies operates a commercial office and a smaller pilot site dedicated to tests, trials, and evaluations in Hillerød.

2018
- Founded by Martin Rose and Jesper Breum

2019
- Establish corporate infrastructure and initiates identification of therapeutic objectives

2020
- Receives authorization from the Danish Medicines Agency to formulate cannabinoid-based prescription drugs, and to handle narcotics

- Opens production site in Hillerød

2021
- Secures €2 million in Seed round

2022
- Submits first patent applications

- Enters commercial contracts to supply products to Germany, United Kingdom, Portugal and Brazil

2023
- Secures €9M in a series A round

- Releases first product (XATEPA®) in Germany and United Kingdom

- Inaugurates 4,000 sqm R&D and production facility in Ølstykke

- Completes pre-clinical trial of TPT0301